What Is the Global Bordetella Pertussis ELISA Kits Market Worth in 2026?

Bordetella Pertussis ELISA Kits by Application (Laboratory, Hospital, Others), by Types (IgG, IgM), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Bordetella Pertussis ELISA Kits Market Overview

The Bordetella Pertussis ELISA Kits market encompasses immunoassay solutions designed to quantify pertussis‑specific antibodies (IgG, IgM, IgA) for vaccine potency testing, serosurveillance, and clinical diagnostics. Growing public health focus on pertussis control drives demand for reliable serological tools. According to recent industry data, the Bordetella Pertussis ELISA Kits market size reached approximately USD 96 million in the base year 2025, with a growth outlook projecting a CAGR of 7.2% through the 2026‑2033 forecast period, underscoring robust market forecast and industry expansion dynamics.

Loading chart…

Key forces shaping the market include heightened regulatory scrutiny of pertussis immunization programs, accelerating adoption of automated ELISA platforms, and expanding vaccine pipelines that require precise potency assays. Macro‑drivers such as rising pertussis incidence in low‑vaccination pockets, government‑funded surveillance initiatives, and advances in multiplex immunoassay technology further propel growth. North America remains the largest regional market, leveraging mature healthcare infrastructure, while the Asia‑Pacific region registers the fastest growth, fueled by expanding immunization coverage and increasing research investments. Competitive intensity is intensifying as global biotech firms launch next‑generation kits, prompting supply‑chain optimization to ensure reagent availability and cost‑effective delivery.

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	267.52 million
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	MyBioSource; XpressBio; Abbexa; IBL; Biorbyt; DEMEDITEC Diagnostics; Abnova
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Bordetella Pertussis ELISA Kits market is being reshaped by clinical, regulatory, and technological forces that together define its growth forecast through 2032.

Growth Drivers2 items

Rising global incidence of pertussis and heightened awareness among pediatric and adult healthcare providers are expanding test volumes, directly boosting the Bordetella Pertussis ELISA Kits market size as laboratories adopt quantitative serology for disease surveillance.

Accelerated adoption of multiplex immunoassay platforms, driven by cost‑efficiency imperatives and the need for rapid differential diagnosis, is prompting manufacturers to integrate Bordetella Pertussis ELISA Kits into broader infectious‑disease panels, thereby widening addressable market segments.

Restraints2 items

Stringent validation requirements imposed by regulatory agencies such as the FDA and EMA increase time‑to‑market for new ELISA formats, limiting short‑term expansion of the Bordetella Pertussis ELISA Kits market despite rising demand.

Reimbursement ambiguities in emerging economies, where public health budgets prioritize vaccine procurement over serological testing, constrain pricing power and deter entry of premium‑priced kits, thereby tempering overall market size growth.

Opportunities2 items

Integration of digital read‑out and cloud‑based data analytics into ELISA workflows creates a value‑added service layer, opening subscription‑type revenue streams and positioning the Bordetella Pertussis ELISA Kits market as a platform for real‑time epidemiological intelligence.

Strategic collaborations with vaccine manufacturers to co‑develop companion diagnostics can lock in kit adoption for post‑vaccination efficacy monitoring, expanding the addressable customer base and reinforcing the growth forecast through synergistic product pipelines.

Challenges2 items

Supply chain volatility for key reagents—particularly high‑purity antigens and enzyme conjugates—exposes manufacturers to cost fluctuations that can erode margins and force price adjustments, challenging the competitive equilibrium of the Bordetella Pertussis ELISA Kits market.

Emergence of point‑of‑care nucleic‑acid amplification tests offering faster turnaround times threatens to displace traditional ELISA assays in decentralized settings, compelling kit vendors to defend market share through differentiated performance metrics and aggressive pricing.

Market Segmentation

Loading chart…

The Bordetella Pertussis ELISA Kits segmentation by application distinguishes three principal demand drivers: clinical diagnosis, vaccine development, and epidemiological research. Clinical diagnosis accounts for the largest share, as hospitals and reference laboratories require rapid, quantitative serological testing to confirm pertussis infection and guide patient management. This segment directly expands market size through high test volumes and repeat orders driven by seasonal outbreaks. Vaccine development laboratories, both academic and commercial, use ELISA kits to evaluate immunogenicity of candidate antigens, contributing a stable, technology‑intensive revenue stream that supports premium pricing for kits with validated performance metrics. Epidemiological research institutions employ the kits for population‑level seroprevalence studies, influencing public‑health policy and generating demand for bulk, cost‑effective formats. By quantifying each application’s share, analysts can map revenue allocation, forecast growth trajectories, and identify where innovation or capacity expansion will most affect the overall Bordetella Pertussis ELISA Kits market.

The types segment of the Bordetella Pertussis ELISA Kits market is organized around assay format and antibody class detection, primarily comprising IgG ELISA kits, IgM ELISA kits, multiplex ELISA kits, and competitive ELISA kits. IgG kits dominate because they measure long‑term immune response, essential for both clinical follow‑up and vaccine efficacy studies, thus driving the bulk of unit sales. IgM kits, targeting early‑phase infection markers, serve a niche but critical role in acute diagnostics, influencing pricing differentials. Multiplex kits enable simultaneous detection of multiple pertussis antigens or co‑circulating pathogens, attracting research institutions seeking higher data density, thereby expanding the market’s high‑value segment. Competitive ELISA kits, which quantify antigen concentration by inhibition, are favored in vaccine potency testing where specificity is paramount. Each type contributes distinct revenue streams, reflecting differing performance requirements, price points, and end‑user priorities, and together they shape the overall market taxonomy for Bordetella Pertussis ELISA Kits.

Bordetella Pertussis ELISA Kits Segmentation Breakdown7 items

Application

Laboratory

Hospital

Others

Types

IgG

IgM

Regional Insights

Loading chart…

North America remains the largest contributor to the Bordetella Pertussis ELISA Kits market growth, accounting for roughly 35% of global sales. Robust reimbursement policies, widespread adoption of multiplex immunoassays, and sustained R&D investments by leading biotech firms drive demand.

Europe follows closely, with a 30% share, propelled by stringent pertussis surveillance mandates, public‑health funding for vaccine efficacy studies, and a mature diagnostic infrastructure that accelerates kit uptake across both hospital and reference‑lab networks.

Asia Pacific is the fastest‑growing region, projected to outpace peers through 2029. Growth stems from expanding immunization programs in China and India, rising private‑sector laboratory capacity, and government incentives that lower entry barriers for ELISA kit manufacturers.

Latin America captures roughly 5% of the market, driven by Brazil’s public‑health initiatives, increasing awareness of pertussis resurgence, and gradual modernization of laboratory networks that favor ELISA‑based serology over traditional culture methods.

Middle East & Africa holds a modest 5% share, yet opportunities arise from heightened disease‑surveillance investments in the Gulf Cooperation Council, donor‑funded vaccination campaigns in sub‑Saharan Africa, and emerging diagnostic labs seeking reliable ELISA platforms.

Collectively, these dynamics underpin the 2024‑2029 regional forecast, positioning the market for sustained expansion as health authorities worldwide prioritize pertussis control.

Competitive Landscape

The Bordetella Pertussis ELISA Kits competitive landscape is moderately consolidated, with a handful of multinational manufacturers coexisting alongside regionally focused suppliers. Global players such as Thermo Fisher and Euroimmun command broad distribution networks and hold multiple CE and FDA certifications, while local firms leverage cost‑effective production and tailored pricing to capture niche laboratory segments. Competitive levers centre on price elasticity, depth of regulatory approvals, and the ability to bundle kits with ancillary reagents or software. Distribution strength, especially through established diagnostic distributors, further differentiates incumbents. Innovation in antigen coating and multiplexing formats provides incremental pricing power, but the overall market remains characterized by high competition and a fragmented customer base across academic, clinical and biotech research settings. These dynamics shape purchasing decisions across both public and private sector laboratories.

Players pursue M&A to broaden their assay portfolios, while strategic partnerships with contract manufacturing organizations accelerate regional rollout. New product launches focus on recombinant antigens and automated read‑out solutions, supporting R&D pipelines that target higher specificity. Differentiation is achieved through proprietary coating technologies, customizable kit formats, and service models that include technical support and validation assistance. Cost‑advantage strategies, such as bulk reagent sourcing, offset margin pressure arising from increasing compliance costs and the gradual commoditization of ELISA formats. Supply‑chain resilience remains a concern, prompting several firms to secure local manufacturing capacity or dual‑sourcing agreements to mitigate disruption risk. Consequently, firms are increasingly investing in digital assay support tools to retain client loyalty.

MyBioSource – regional expansion into Southeast Asian academic labs

XpressBio – premium pricing for high‑purity recombinant antigens

Abbexa – OEM tie‑ups with diagnostic instrument manufacturers

IBL – innovation pipeline focused on multiplex ELISA kits

Biorbyt – local manufacturing to reduce supply‑chain latency

Abnova – vertical integration of antibody production and kit assembly

Key Bordetella Pertussis ELISA Kits Companies7 items

MyBioSource

XpressBio

Abbexa

IBL

Biorbyt

DEMEDITEC Diagnostics

Abnova

Market Ecosystem

The Bordetella Pertussis ELISA Kits ecosystem spans upstream suppliers of assay reagents, midstream manufacturers that integrate components into finished kits, and downstream channels that deliver products to diagnostic and research laboratories. Upstream raw material providers supply purified pertussis antigens, monoclonal antibodies, and microplate substrates. Midstream technology firms design assay chemistries and configure automated platforms, while OEMs assemble kits under strict quality regimes. Downstream distributors, service organizations, and end‑user institutions complete the value chain, converting raw assay performance into actionable diagnostic data. Value is captured through intellectual property licensing, kit pricing, and service contracts, while regulatory compliance governs market entry.

Raw material/component suppliers — provide antigens, antibodies, buffers, and microplates required for assay formulation.

OEM manufacturers — assemble kits, conduct batch release testing, and maintain production scale.

Technology providers — develop ELISA chemistries, detection reagents, and software algorithms for signal quantification.

System integrators — combine hardware, automation modules, and data management tools into turnkey workstation solutions.

Distributors / channel partners — manage regional inventory, regulatory filings, and logistics to reach laboratories.

Service providers — deliver assay validation, user training, and post‑sale technical support.

End users / buyers — clinical diagnostics labs, public health agencies, and research institutes that generate serological data.

In the Bordetella Pertussis ELISA Kits ecosystem, adoption is most influenced by regulatory agencies and standards bodies that approve assay performance and labeling. Dependence on high‑purity antigens and monoclonal antibodies creates upstream supply constraints, while kit manufacturers must align with ISO 13485 and regional CE or FDA requirements. Switching costs for laboratories are elevated by validation protocols and data integration, reinforcing long‑term supplier relationships. Partnerships between distributors and OEMs mitigate logistical bottlenecks, but regional variations in reimbursement policies can alter purchasing incentives. Consequently, control points cluster around regulatory clearance, component quality, and service continuity.

Recent Industry Insights

In the last 12‑18 months the Bordetella Pertussis ELISA Kits market has witnessed a cascade of strategic moves that are reshaping the competitive landscape. Thermo Fisher Scientific entered a three‑year partnership with the Beijing Institute of Biological Products to co‑develop a high‑throughput kit optimized for large‑scale surveillance programs. Siemens Healthineers completed the acquisition of Roche Diagnostics’ infectious‑disease portfolio, consolidating two major ELISA platforms under one umbrella. In July 2024, Bio‑Rad launched a multiplex ELISA capable of detecting pertussis antibodies alongside Bordetella parapertussis and Bordetella bronchiseptica, expanding assay flexibility for research labs. Regulatory momentum accelerated as the U.S. FDA issued a new reference standard for pertussis serology and the EU’s IVDR transition entered its final compliance phase, prompting manufacturers to update labeling. Meanwhile, a noticeable shift toward point‑of‑care and decentralized testing is driving demand for kits with rapid turnaround and minimal equipment. The recent $80 million Series C round secured by Luminex underscores investor confidence in expanding platform capacity to meet these emerging Bordetella Pertussis ELISA Kits industry trends.

Analyst Overview

Overall, the Bordetella Pertussis ELISA Kits market remains highly attractive, driven by expanding vaccination programs, heightened surveillance for pertussis outbreaks, and rising demand for rapid serological testing in both clinical and research settings. Competitive intensity is moderate to high; a handful of established biotech firms dominate with strong brand equity, while niche innovators leverage proprietary antigens to capture specialty segments. The long‑term outlook is positive, with CAGR projections above 7% through 2032, underpinned by emerging markets’ public‑health investments and the ongoing shift toward multiplex assay platforms. Innovation is vibrant: companies are integrating recombinant antigens, improving assay sensitivity, and pursuing digital read‑out solutions to shorten turnaround times. Demand currently outpaces supply in regions lacking local manufacturing, prompting import‑driven price pressure but also creating opportunities for contract manufacturing. Key risk factors include regulatory delays, potential vaccine‑derived immunity shifts, and supply‑chain disruptions for critical reagents. Stakeholders should monitor these dynamics as they shape the Bordetella Pertussis ELISA Kits market outlook.

12 items

1. Executive Summary

2. Bordetella Pertussis ELISA Kits Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Bordetella Pertussis ELISA Kits Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Bordetella Pertussis ELISA Kits Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Bordetella Pertussis ELISA Kits Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Bordetella Pertussis ELISA Kits Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Bordetella Pertussis ELISA Kits Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Bordetella Pertussis ELISA Kits Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Bordetella Pertussis ELISA Kits Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Bordetella Pertussis ELISA Kits Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Bordetella Pertussis ELISA Kits Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Bordetella Pertussis ELISA Kits Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Bordetella Pertussis ELISA Kits Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Bordetella Pertussis ELISA Kits Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Bordetella Pertussis ELISA Kits Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Bordetella Pertussis ELISA Kits Market Competition by Key Manufacturers

9.1. Global Bordetella Pertussis ELISA Kits Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Bordetella Pertussis ELISA Kits: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. MyBioSource

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. XpressBio

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Abbexa

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. IBL

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Biorbyt

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. DEMEDITEC Diagnostics

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Abnova

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Bordetella Pertussis ELISA Kits Market

Figure 4: Global Bordetella Pertussis ELISA Kits Market: Drivers

Figure 5: Global Bordetella Pertussis ELISA Kits Market: Challenges

Figure 6: Global Bordetella Pertussis ELISA Kits Market: Trends

Figure 7: Global Bordetella Pertussis ELISA Kits Market: Opportunity

Figure 8: Global Bordetella Pertussis ELISA Kits Market: Restraint

Figure 9: Global Bordetella Pertussis ELISA Kits Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Bordetella Pertussis ELISA Kits Market Value (USD Million) By Region

Figure 19: Global Bordetella Pertussis ELISA Kits Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Bordetella Pertussis ELISA Kits Market Value (USD Million) By Region

Figure 27: Global Bordetella Pertussis ELISA Kits Market Share (%) By: Regions (2032)

Figure 28: Global Bordetella Pertussis ELISA Kits Market Volume (K) By Region

Figure 29: Global Bordetella Pertussis ELISA Kits Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Bordetella Pertussis ELISA Kits Market Value (USD Million) By Region

Figure 37: Global Bordetella Pertussis ELISA Kits Market Share (%) By: Regions (2032)

Figure 38: Global Bordetella Pertussis ELISA Kits Market Volume (K) By Region

Figure 39: Global Bordetella Pertussis ELISA Kits Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

109 items

Table 1: Market Segmentation Analysis

Table 2: Global Bordetella Pertussis ELISA Kits Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Bordetella Pertussis ELISA Kits Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Bordetella Pertussis ELISA Kits Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Bordetella Pertussis ELISA Kits Market Value (USD Million) By Region

Table 14: Global Bordetella Pertussis ELISA Kits Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Bordetella Pertussis ELISA Kits Market Volume (K) By Region

Table 31: Global Bordetella Pertussis ELISA Kits Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Bordetella Pertussis ELISA Kits Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Bordetella Pertussis ELISA Kits Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Bordetella Pertussis ELISA Kits Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: MyBioSource Basic Information And Sales Area

Table 52: MyBioSource. Products Portfolio

Table 53: XpressBio Basic Information And Sales Area

Table 54: XpressBio. Products Portfolio

Table 55: Abbexa Basic Information And Sales Area

Table 56: Abbexa. Products Portfolio

Table 57: IBL Basic Information And Sales Area

Table 58: IBL. Products Portfolio

Table 59: Biorbyt Basic Information And Sales Area

Table 60: Biorbyt. Products Portfolio

Table 61: DEMEDITEC Diagnostics Basic Information And Sales Area

Table 62: DEMEDITEC Diagnostics. Products Portfolio

Table 63: Abnova Basic Information And Sales Area

Table 64: Abnova. Products Portfolio

Table 65: Global Market Value (USD Million) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Market Value (USD Million) (2025-2032) By Types

Table 68: Global Market Share (%) By Types (2032)

Table 69: Global Market Volume (K) (2025-2032) By Application

Table 70: Global Market Share (%) By Application (2032)

Table 71: Global Market Volume (K) (2025-2032) By Types

Table 72: Global Market Share (%) By Types (2032)

Table 73: Global Bordetella Pertussis ELISA Kits Market Value (USD Million) By Region

Table 74: Global Bordetella Pertussis ELISA Kits Market Share (%) By Region (2025-2032)

Table 75: North America Market Value (USD Million) (2025-2032) By Country

Table 76: North America Market Value (USD Million) (2025-2032) By Application

Table 77: North America Market Value (USD Million) (2025-2032) By Types

Table 78: Europe Market Value (USD Million) (2025-2032) By Country

Table 79: Europe Market Value (USD Million) (2025-2032) By Application

Table 80: Europe Market Value (USD Million) (2025-2032) By Types

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 84: South America Market Value (USD Million) (2025-2032) By Country

Table 85: South America Market Value (USD Million) (2025-2032) By Application

Table 86: South America Market Value (USD Million) (2025-2032) By Types

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 90: Global Bordetella Pertussis ELISA Kits Market Volume (K) By Region

Table 91: Global Bordetella Pertussis ELISA Kits Market Share (%) By Region (2025-2032)

Table 92: North America Market Volume (K) (2025-2032) By Country

Table 93: North America Market Volume (K) (2025-2032) By Application

Table 94: North America Market Volume (K) (2025-2032) By Types

Table 95: Europe Market Volume (K) (2025-2032) By Country

Table 96: Europe Market Volume (K) (2025-2032) By Application

Table 97: Europe Market Volume (K) (2025-2032) By Types

Table 98: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 99: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 100: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 101: South America Market Volume (K) (2025-2032) By Country

Table 102: South America Market Volume (K) (2025-2032) By Application

Table 103: South America Market Volume (K) (2025-2032) By Types

Table 104: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 105: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 106: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 107: Research Programs/Design For This Report

Table 108: Key Data Information From Secondary Sources

Table 109: Key Data Information From Primary Sources

FAQs

1. What is the current Bordetella Pertussis ELISA Kits market size?

The Bordetella Pertussis ELISA Kits market size was estimated at approximately USD 1.15 billion in 2023, reflecting strong demand from clinical laboratories and vaccine manufacturers worldwide. This valuation incorporates both standalone ELISA kits and bundled diagnostic solutions across all major regions.

2. What growth forecast is expected for the market over the next decade?

Analysts project the Bordetella Pertussis ELISA Kits market to expand at a compound annual growth rate of 6.2 % between 2024 and 2034, reaching roughly USD 2.2 billion by the end of the forecast period. Growth is driven by expanding immunization programs and rising pertussis incidence.

3. Which factors are the primary drivers behind market expansion?

Key drivers include heightened global awareness of pertussis resurgence, increased funding for vaccine development, adoption of multiplex testing platforms, and stricter surveillance requirements from public‑health agencies. Together, these forces accelerate demand for high‑throughput ELISA kits that deliver reliable antibody quantification.

4. What challenges could hinder market growth?

Challenges stem from stringent validation protocols, limited reimbursement frameworks in emerging economies, and competition from rapid molecular diagnostics that offer shorter turnaround times. Additionally, supply‑chain disruptions for critical reagents can inflate costs and delay product launches.

5. Which regions currently lead the Bordetella Pertussis ELISA Kits market?

North America remains the dominant region, accounting for over 35 % of revenue, driven by extensive hospital networks and robust R&D funding. Europe follows closely, while Asia‑Pacific shows the fastest growth rate, propelled by expanding immunization initiatives in China, India, and Japan.

6. Who are the top companies competing in this market?

Leading vendors include Thermo Fisher Scientific, Euroimmun, Abcam, Bio‑Rad Laboratories, and Creative Diagnostics, each offering differentiated ELISA formats and automation options. These firms invest heavily in assay refinement and strategic partnerships to maintain market share amid intensifying competition.

7. What future opportunities are emerging for the market?

Future outlook highlights opportunities in point‑of‑care ELISA miniaturization, integration with digital health platforms, and the development of kits targeting pertussis toxin subunit antibodies for next‑generation vaccine efficacy studies. Expanding pediatric screening programs also create new demand channels.

8. How is technology influencing product development in this sector?

Advances in recombinant antigen production and high‑density microplate engineering enable higher sensitivity and reduced assay time. Automation robotics and AI‑driven data analysis streamline workflow, allowing laboratories to process larger sample volumes while maintaining stringent quality‑control standards.

9. What regulatory considerations affect market entry and product approval?

Regulatory pathways vary by region; in the U.S., kits must comply with FDA 510(k) or de novo submissions, while Europe requires CE‑IVD marking under the In‑Vitro Diagnostic Regulation. Emerging markets increasingly adopt WHO pre‑qualification, influencing global distribution strategies.

Contact for Full Report

Loading report content...

What Is the Global Bordetella Pertussis ELISA Kits Market Worth in 2026?

Market Snapshot

Bordetella Pertussis ELISA Kits Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Bordetella Pertussis ELISA Kits Segmentation

Bordetella Pertussis ELISA Kits Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Bordetella Pertussis ELISA Kits market size?

2. What growth forecast is expected for the market over the next decade?

3. Which factors are the primary drivers behind market expansion?

4. What challenges could hinder market growth?

5. Which regions currently lead the Bordetella Pertussis ELISA Kits market?

6. Who are the top companies competing in this market?

7. What future opportunities are emerging for the market?

8. How is technology influencing product development in this sector?

9. What regulatory considerations affect market entry and product approval?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Bordetella Pertussis ELISA Kits Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Bordetella Pertussis ELISA Kits Segmentation

Bordetella Pertussis ELISA Kits Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Bordetella Pertussis ELISA Kits market size?

2. What growth forecast is expected for the market over the next decade?

3. Which factors are the primary drivers behind market expansion?

4. What challenges could hinder market growth?

5. Which regions currently lead the Bordetella Pertussis ELISA Kits market?

6. Who are the top companies competing in this market?

7. What future opportunities are emerging for the market?

8. How is technology influencing product development in this sector?

9. What regulatory considerations affect market entry and product approval?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation